Cessatech presents new data on paediatric pain relief at the PAGE conference in Rome favouring its lead candidate CT001
· Optimal drug exposure for effective pain management, significant findings revealed that relative drug exposure is much higher in young children. · Enhanced understanding of paediatric nasal drug delivery underscores the importance of age-specific considerations in nasal drug delivery. · Efficacy of CT001 administration. solidifies the opioid-sparing advantage of the CT001 formulation, making it a safer option for paediatric patients.On 28 June – Cessatech A/S (“Cessatech” or “the Company”) announces that the presentation is now available from the Population Approach Group Europe (